Paris, November 18, 2009 – Cellectis S.A. (Alternext: ALCLS), the French genome engineering specialist, has published the full text of a pretrial judge’s ruling (dated April 9th, 2009) on its corporate website - http://www.cellectis.com/news-events/. Contrary to Genoway’s statement in a press release dated November 13, 2009, the pretrial order did not suspend the sublicense termination issued by Cellectis on December 30, 2008.
Since this date and in application of the Tribunal de Grande instance de Paris court’s ruling dated November 12, 2009, the products and services obtained using the homologous recombination process and sold by Genoway are products to which Genoway has no sublicense rights whatsoever.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
